Scientific & Medical Advisory Board
Randall K. Wolf, M.D., FACS, FACC
Dr. Randall Wolf is an internationally recognized key opinion leader in cardiothoracic surgery. He is a surgical innovator and has pioneered since 2000 the minimally invasive surgical procedure, the Wolf Minimaze, to treat atrial fibrillation (AF).
Dr. Wolf was the first heart surgeon to perform DaVinci robotic cardiac procedures in North America and was the first DaVinci proctor. He has performed cardiac surgery in 20 countries. Dr. Wolf is Professor of Surgery at McGovern Medical School, Department of Cardiothoracic and Vascular Surgery, University of Health Science Center at Houston (UTHealth). Dr. Wolf is also the Surgical Director of the Atrial Fibrillation Clinic Cardiothoracic and Vascular Institute at Memorial Hermann Hospitals, Houston, TX. Dr. Wolf is Honorary Professor of Surgery at Capital University in Beijing, China.
Dr. Wolf’s research and area of expertise include: minimally invasive atrial fibrillation procedures and devices, minimally invasive heart and lung surgery, robotics in cardiac surgery, anastomotic devices, surgical sealants, biosurgery, video thoracoscopy and video-assisted thoracic surgery, lung volume reduction for emphysema and thoracoscopic spine surgery, phrenic nerve pacemakers MEMS technology.
Dr. Wolf has published over 100 peer-reviewed papers and textbook chapters. He is frequently invited to present his work at scientific conferences around the world.
Robert B. Raffa, Ph.D.
Dr. Robert B. Raffa has devoted his professional career to pharmacology and understanding the balance between therapeutic utility and abuse potential of drugs. Previously, he was team co-leader for analgesics drug discovery at Johnson & Johnson. Dr. Raffa has received more than $3 million in research funding from National Institutes of Health and other sources for investigation of drug action and drug abuse issues. In addition, Dr. Raffa has published over 300 peer-reviewed papers, is the co-author or editor of several books on pharmacology and thermodynamics and is a co-editor of the Journal of Clinical Pharmacy and Therapeutics. He is a past president of the Mid-Atlantic Pharmacology Society, and he lectures and consults worldwide on analgesics and analgesic combinations.
Robert D. Colucci, PharmD.
Dr. Colucci has over 20-years’ experience in pharmaceutical research and development and has been involved in all phases of clinical research and drug development. Dr. Colucci has held leadership and management positions in the development, planning, and execution of numerous analgesic, CNS, and cardiovascular therapies. He has been employed by Schering-Plough Research Institute, Purdue Pharma L.P., New River Pharmaceuticals, and Javelin Pharmaceuticals. He now serves as an independent consultant for various pharmaceutical and medical device companies.
Dr. Colucci is a member and has been active in numerous professional organizations including the American College of Clinical Pharmacology, College on Problems of Drug Dependence, and the Society of Critical Care Medicine. He is a fellow in both the American College of Clinical Pharmacology and the Society of Critical Care Medicine. He has authored over 125 abstracts and scientific publications in the area of clinical pharmacology and drug development and he holds 15 pharmaceutical patents. Dr. Colucci has held academic appointments at Rutgers University, Mount Sinai School of Medicine, and the University of Connecticut. Additionally, he has been a reviewer and served on the editorial boards for leading clinical pharmacology and pharmacy journals.
Dr. Colucci received a Bachelor of Science Degree in Pharmacy and a Doctor of Pharmacy Degree from the Massachusetts College of Pharmacy and Allied Health Science in Boston, Massachusetts. He completed a 2-year Cardiovascular Therapeutic Fellowship at Hartford Hospital and the University of Connecticut.